Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Pulmonology
•
Pulmonary Infections
What is your approach to duration of antibiotic therapy for treatment of a bacterial lung abscess?
Related Questions
Do you treat non-albicans strains of Candida on sputum culture or BAL in patients who are immunosuppressed?
Is there a specific criteria that you use to determine if a patient with respiratory symptoms should have a multiplex respiratory test performed?
How long do you recommend that a patient wear a mask when resuming biologic infusions following a recent upper respiratory infection?
What is the interpretation of two IGRAs with negative mitogen wells, in the absence of immunosuppression?
Do you consider the use of tocilizumab in patients with COVID pneumonia who have had an improvement in supplemental O2 requirements but have significantly elevated inflammatory markers after day two of remdesivir and dexamethasone?
How would you manage a patient with necrotizing pneumonia due to a susceptible Pseudomonas aeruginosa strain who continues to have significant purulent secretions and worsening imaging while receiving cefepime?
Would you recommend anti-fungal treatment for aspergillus infection for a patient with an incidental finding of worsening ground glass opacities and enlarging nodules on CT chest with positive BAL galactomannan, elevated aspergillus IgE and IgG in an otherwise immunocompetent host with no respiratory symptoms?
How do you consider sending fungal studies in a patient with pneumonia?
Would you recommend antifungal treatment or observation without therapy in an immunocompetent patient with a pulmonary nodule who underwent malignancy workup and was found to have yeast forms consistent with histoplasma on GMS stain?
Would you start treatment for MAC in a patient with nodular bronchiectatic disease who has demonstrated radiographic progression but remains asymptomatic and smear-negative?
